Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Myriad discovers gene's role as tumor suppressor

Oct. 9, 1997

Epimmune issued U.S. patent for cancer therapeutic

Oct. 7, 1997

Merck & Co. focuses on farnesyltransferase inhibitors

Oct. 7, 1997

Kyowa Hakko's cytostatic agents progress in U.S. clinical trials

Oct. 6, 1997

Clinical pharmacokinetic study of panomifene described

Oct. 6, 1997

Gd-Tex in phase Ib: safety profile and maximum tolerated dose

Oct. 6, 1997

Femara launched in U.S.

Oct. 3, 1997

Sugen's angiogenesis inhibitor SU-5416 enters phase I

Oct. 3, 1997

Favorable phase II/III data for Targretin in CTCL reported at dermatology congress

Oct. 2, 1997

Safety profile of VRCTC-310 established in rabbits

Oct. 2, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...